Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Other Accumulated Expenses (2023 - 2025)

Verrica Pharmaceuticals (VRCA) has 3 years of Other Accumulated Expenses data on record, last reported at $366000.0 in Q2 2025.

  • For Q2 2025, Other Accumulated Expenses rose 21.59% year-over-year to $366000.0; the TTM value through Jun 2025 reached $366000.0, up 21.59%, while the annual FY2024 figure was $105000.0, 56.97% down from the prior year.
  • Other Accumulated Expenses reached $366000.0 in Q2 2025 per VRCA's latest filing, up from $166000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $428000.0 in Q3 2024 and bottomed at $105000.0 in Q4 2024.
  • Average Other Accumulated Expenses over 3 years is $276625.0, with a median of $291500.0 recorded in 2023.
  • The widest YoY moves for Other Accumulated Expenses: up 51.77% in 2024, down 56.97% in 2024.
  • A 3-year view of Other Accumulated Expenses shows it stood at $244000.0 in 2023, then plummeted by 56.97% to $105000.0 in 2024, then surged by 248.57% to $366000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $366000.0 in Q2 2025, $166000.0 in Q1 2025, and $105000.0 in Q4 2024.